Toggle Nav

Valdecoxib

Catalog No.
B1459
COX-2 inhibitor
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$50.00
In stock
10mg
$80.00
In stock
50mg
$320.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Valdecoxib is a potent and selective inhibitor of cyclooxygenase-2 (COX-2) with IC50 value of 5nM [1].

Valdecoxib is developed for the management of pain and inflammation. Valdecoxib and its intravenous prodrug parecoxib exert significant opioid-sparing effects after dental, gynecologic, orthopedic and other noncardiac surgical procedures. In the cellular assay, valdecoxib shows inhibitory activity on human recombinant COX-2 with IC50 value of 5nM. It shows no significant effect on COX-1 with IC50 value of 140μM. In the ex vivo assay using human whole blood, valdecoxib prevents PGE2 production with IC50 value of 0.89μM. Moreover, oral administration of valdecoxib exerts chronic anti-inflammatory activity with ED50 value of 0.032 mg/kg/day in the rat adjuvant arthritis model. In addition, valdecoxib is reported to have cardiovascular risk adverse effect in patients undergoing CABG [1, 2].

References:
[1] Talley J J, Brown D L, Carter J S, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. Journal of medicinal chemistry, 2000, 43(5): 775-777.
[2] Nussmeier N A, Whelton A A, Brown M T, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New England Journal of Medicine, 2005, 352(11): 1081-1091.

Chemical Properties

StorageStore at -20°C
M.Wt314.36
Cas No.181695-72-7
FormulaC16H14N2O3S
Solubility≥15.72mg/mL in DMSO
Chemical Name4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide
SDFDownload SDF
Canonical SMILESCC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Protocol

In vitro experiment [1]:

Samples

Whole blood

Preparation method

The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.

Reacting condition

Overnight for assessment of the extent of COX-2 inhibition; 25 mins for assessment of the extent of COX-1 inhibition

Applications

In the assay for assessment of the extent of COX-2 inhibition, Valdecoxib inhibited lipopolysaccharide-induced PGE2 production, with an IC50 value of 0.89 μM. In the assay for assessment of the extent of COX-1 inhibition, Valdecoxib inhibited TXB2 production, with an IC50 value of 25.4 μM.

Animal experiment [1]:

Animal models

Male SD rats

Dosage form

0.02, 0.032 or 10.2 mg/kg; p.o.

Applications

In SD rats, Valdecoxib inhibited carrageenan-induced foot pad edema, with an ED50 value of 10.2 mg/kg. In a rat adjuvant arthritis model, Valdecoxib also showed chronic anti-inflammatory activity, with an ED50 value of 0.032 mg/kg/day. In addition, Valdecoxib inhibited prostaglandin production at the inflammatory site in a carrageenan-induced air pouch model, with an ED50 value of 0.02 mg/kg.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Talley J J, Brown D L, Carter J S, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. Journal of medicinal chemistry, 2000, 43(5): 775-777.

Quality Control